Two research scientists looking at microscope slides

Evgen encouraged by trials progress

Drug discovery group Evgen Pharma said it is pleased with its progress on treatments under development. The business focuses on treatments for cancer, strokes and Multiple Sclerosis. The company also revealed encouraging data in recent preliminary reports from pre-clinical programmes in triple negative breast cancer, glioblastoma and ischaemic stroke.

Chief executive Stephen Franklin said: “We were delighted with the positive breast cancer interim data showing good tolerability and efficacy in this very difficult to treat patient population and are hopeful that these trends will be maintained in the final analysis…we are excited about the near-term prospects of the company.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.